Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sees no need to change its 2010 guidance based on health care reform and maintains its forecast for mid-single-digit growth.
You may also be interested in...
Dusk And Dawn In Emerging Markets? Pharmas Find Growth Elsewhere Offset Turkish Price Cuts
Each market is different, but even more so in emerging markets. The world's sixth-largest drug maker Novartis' first quarter results showed that strong growth from top pharmemerging markets, China, India, Brazil, and South Korea "more than" offset an across-the-board drug price cut in Turkey
Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years